Advances in chemotherapy for advanced colorectal cancer

李文桦; 张　文

doi:10.3969/j.issn.1007-3969.2015.11.007

您当前的位置：

首页 >

文章列表页 >

Advances in chemotherapy for advanced colorectal cancer

更新时间：2025-12-31

- Advances in chemotherapy for advanced colorectal cancer
- China Oncology Vol. 25, Issue 11, Pages: 877-889(2015)
- 作者机构：
  
  复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.11.007
  CLC：
- Published Online：01 February 2016，
  
  Published：01 February 2015
- 稿件说明：
移动端阅览
李文桦,张　文. 晚期结直肠癌的化疗进展[J]. 中国癌症杂志, 2015, 25(11): 877-889.

李文桦, 张　文. Advances in chemotherapy for advanced colorectal cancer[J]. China Oncology, 2015, 25(11): 877-889.
李文桦,张　文. 晚期结直肠癌的化疗进展[J]. 中国癌症杂志, 2015, 25(11): 877-889. DOI： 10.3969/j.issn.1007-3969.2015.11.007.

李文桦, 张　文. Advances in chemotherapy for advanced colorectal cancer[J]. China Oncology, 2015, 25(11): 877-889. DOI： 10.3969/j.issn.1007-3969.2015.11.007.

摘要

化疗是晚期结直肠癌的主要治疗手段，以氟尿嘧啶(5-fluorouracil，5-FU)、奥沙利铂和伊立替康为主的三药是晚期肠癌治疗的重要药物，联合化疗和“打打停停”的治疗模式在提高疗效的同时兼顾了治疗的耐受性。新的化疗药物雷替曲塞、替吉奥和TAS-102也在临床中获得应用。就晚期结直肠癌化疗的进展进行综述。

Abstract

Chemotherapy is the main treatment approach for advanced colorectal cancer. The 5-fluorouracil (5-FU)

oxaliplatin and irinotecan are three major chemotherapeutic drugs. The combined chemotherapy and “stop and go” treatment mode increase the efficacy and patients’ tolerance. The new drugs

raltitrexed

S-1 and TAS-102

have been approved for use in cancer treatment. This article reviews the new development in chemotherapy for the treatment of advanced colorectal cancer.

关键词

Keywords

references

Views

5139

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Application value of combined coagulation function indicators in monitoring hypercoagulable state of patients with colorectal cancer after chemotherapy

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Mechanisms underlying tepoxalin-mediated regulation of cell growth and chemoresistance via ABCB1 in colorectal cancer

Research progress and prospects of exercise intervention in comprehensive management of colorectal cancer

Advances and future perspectives of neoadjuvant immunotherapy in colorectal cancer

Related Author

Yue LU

Renquan LU

Jie ZHANG

Hui ZHENG

LIU Miao

LI Jinze

WU Chensi

ZHANG Fengbin

Related Institution

Department of Clinical Laboratory, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Pathology, the Fourth Hospital of Hebei Medical University

Department of General Surgery, Shanghai Pudong New District Zhoupu Hospital

Department of Gastroenterology, Shanghai Pudong New District Zhoupu Hospital

AI问答

⁰